QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Odyssey Therapeutics, Inc. (ODTX)

Healthcare

No action
Fundamental
2
Sentiment
3
Technical
2

Do Nothing: fundamentalScore is 2 (below the required floor of 3), which blocks any bullish entry regardless of the chart; independently the chart scores only 2 (price 19.14 below SMA20/SMA50/EMA9/EMA21 and VWAP, MACD below zero), a pullback limit is countertrend by rule (price < SMA50 with MACD < 0), and no breakout stop qualifies (a trigger above the 19.76 high leaves 1.69 = 0.96 ATR of risk, under the 1.0-ATR floor at 9.20% ATR).

Analysis as of 2026-11-13· more than 2 trading days ago

Company overview

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases. Its pipeline includes several drug candidates targeting key pathways involved in these conditions. Founded in 2021, the company is headquartered in Boston, Massachusetts.

Fundamental

weak
Fundamental2
Weak fundamentals

Odyssey Therapeutics shows weak fundamentals with no revenue and a binary risk profile, despite a strong balance sheet.

Pre-revenue clinical-stage immunology company with a strong balance sheet and a binary pipeline. Product and collaboration revenue is now zero, trailing losses run near $178 million with roughly $143 million of annual operating cash burn, and funding beyond 2028 will require substantial additional capital. Liquidity of $387 million, no funded debt, a runway into the second half of 2028 and positive Phase 2a OD-001 data offset those negatives, but earnings-based valuation metrics carry no signal, the DCF models break down at negative per-share values, and the next hard catalyst is second-half-2027 topline data. Weak operating fundamentals with elevated, binary risk - funded, but not yet compelling on fundamentals alone.

Sentiment

fair
Sentiment3
Mixed sentiment

Sentiment is mixed, with recent positive sell-side coverage but no immediate catalysts.

Dominant catalyst is sell-side validation — HC Wainwright assumed coverage at Buy with a $40 target (2026-11-06) and UBS initiated at Buy with $27 (2026-10-31), both announced-confidence and layered on a 2026-11-04 Q3 print that reaffirmed $387M of cash and runway into 2H 2028 — but every leg is trailing and only partially priced, and the 2026-10-20 Phase 2a OD-001 data falls outside the 14-day actionability window. Media sentiment is flat rather than improving (baseline polarity ≈ +0.14 as returned, ≈ +0.23 on-topic, versus scoring ≈ +0.07) and retail is unmeasurable (Reddit 403), so this is a mixed, forming setup; Red-Flag Screen clean, no cap applied.

Technical

weak
Technical2
Weak/neutral chart

The technical indicators show a weak-to-neutral chart with price below key averages and no confirmed uptrend.

Chart reads weak-to-neutral and bounce-only: ODTX at 19.14 sits below its SMA20 (19.53), SMA50 (20.64), EMA9 (19.74), EMA21 (19.67) and daily VWAP (19.28) after a failed rally that topped at 22.36 on 2026-11-04 and has printed lower highs since (21.21 on 11-11, 20.81 on 11-12, 19.76 on 11-13). MACD is below zero (-0.05) but above its signal (-0.17) with a positive histogram (0.13), so momentum is repairing without a confirmed uptrend; RSI14 46.79 is neutral, Williams %R -74.02 is soft, and ADX14 23.08 describes a moderate trend pointing down, not up. ATR14 is 1.76 (9.20% of price) - high volatility that would demand a full 1.0-ATR stop, and a breakout trigger above the 19.76 high leaves only 1.69 = 0.96 ATR of room, under that floor. Score 2 (mostly neutral / weak bearish). Separately, the fundamental override (fundamentalScore 2 < 3) blocks any bullish action regardless of the chart.

You’re looking at 2026-11-13 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.